Abstract

THE DRUG IS USE IN THE TREATMENT OF PNEUMONIA IN COVID 19: REMDESIVIR

Inamdar Minaj*, Wagadare Megha, Gholap Shubham and Parad Aarti

.

Abstract

A prospective (compassionate) open-label study of remdesivir conducted from 23 February to 20 March 2020 at the Luigi Sacco Hospital in Milan, Italy, in patients aged 18 years and older with SARS-CoV-2 pneumonia. Patient enrolled. If you are on a ventilator, have an oxygen saturation in the air of 94% or less, or have a national early warning level 2 of 4 or more. The primary endpoint was change in clinical status based on a 7-point ordinal scale (1 = not hospitalized, resumed normal activities, 7 = death). From 23 February 2020 to 20 March 2020, of her 35 patients who were hospitalized, 18 were in the intensive care unit (ICU) and 17 were in the infectious disease ward (IDW). His 10-day treatment with remdesivir was completed by 22 patients (63%) and discontinued by 13 patients, of whom 8 (22.8%) of him discontinued treatment due to adverse events. Median follow-up was 39 days. On day 28, 14 (82.3%) patients were discharged from the IDW, 2 were still hospitalized, 1 (5.9%) died, and 6 (33.3%) were discharged from the ICU. 8 (44.4%) patients died and 3 (16.7%) died. %) were still on a ventilator, and one (5.6%) improved but was still hospitalized. Hypertransaminasemia and acute renal failure were the most frequently observed serious adverse events (42.8% and 22%).

Keywords: Remdesivir, COVID-19, SARS-CoV-2, Hypertransaminasemia, Pneumonia.